SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-0.59 (-0.90%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close73.45
Bid63.12 x 800
Ask89.93 x 1000
Day's Range72.67 - 73.90
52 Week Range47.75 - 84.37
Avg. Volume821,298
Market Cap11.698B
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
    Zacks11 days ago

    Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?

    Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com14 days ago

    ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates

    Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.

  • Pullback Strategies: 10 Stocks That Could Fall the Fastest
    Investopedia14 days ago

    Pullback Strategies: 10 Stocks That Could Fall the Fastest

    These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.

  • Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic?
    Simply Wall St.15 days ago

    Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic?

    Seattle Genetics, Inc.'s (NASDAQ:SGEN): Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. On 31 December 2018, theRead More...

  • Seattle Genetics' new Bothell campus sells for $63M
    American City Business Journals15 days ago

    Seattle Genetics' new Bothell campus sells for $63M

    Commercial real estate investors are seeking out opportunities in places like Bothell where prices are lower relative to much of the rest of the Eastside.

  • Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
    Zackslast month

    Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

    Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT

    Q4 2018 Seattle Genetics Inc Earnings Call

  • Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
    Zackslast month

    Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

    Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

  • Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today
    Motley Foollast month

    Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today

    Earnings took down some key companies today.

  • Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?
    Investor's Business Dailylast month

    Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?

    Seattle Genetics stock toppled Friday after the biotech met expectations for fourth-quarter sales of cancer treatment Adcetris, but issued soft 2019 guidance for its only approved drug.

  • Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
    Zackslast month

    Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark

    Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.

  • Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed
    Motley Foollast month

    Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed

    With shares up 30% year to date, investors may be taking profits.

  • Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript

    SGEN earnings call for the period ending December 31, 2018.

  • Benzingalast month

    The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

    The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...

  • Markitlast month

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SGEN totaled $1.34 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates
    Zackslast month

    Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

    Seattle Genetics (SGEN) delivered earnings and revenue surprises of -46.15% and 5.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Seattle Genetics: 4Q Earnings Snapshot

    On a per-share basis, the Bothell, Washington-based company said it had a loss of 75 cents. Losses, adjusted for one-time gains and costs, came to 57 cents per share. The results missed Wall Street expectations. ...

  • Investing.comlast month

    Stocks Moving After Hours: Mattel, Skechers, Columbia Sports - Stocks with big gains and losses after hours:

  • What's in the Cards for Glaxo (GSK) This Earnings Season?
    Zackslast month

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Glaxo's (GSK) Vaccines segment is likely to witness strong sales in the fourth quarter.

  • Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
    Zackslast month

    Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?

    Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.

  • Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
    Zacks2 months ago

    Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

    Seattle Genetics (SGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling
    Simply Wall St.2 months ago

    Seattle Genetics, Inc. (NASDAQ:SGEN) Insiders Have Been Selling

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • 5 Biotech Stocks That Could Face M&A Next!
    InvestorPlace2 months ago

    5 Biotech Stocks That Could Face M&A Next!

    Biotech stocks are already making some big waves this year. That's because M&A activity is already surging. Drawn by some big-time values, some of the world's biggest pharmaceutical firms have gone shopping for beaten-down biotech bargains. Already, we've seen Bristol-Meyers (NYSE:BMY) score Celgene (NASDAQ:CELG) for a cool $74 billion in a game-changing acquisition. More recently, Eli Lilly (NYSE:LLY) announced that it was pushing harder into cancer treatments with an $8 billion offer for Loxo Oncology (NASDAQ:LOXO). The question on everyone's minds is "who is next?" InvestorPlace - Stock Market News, Stock Advice & Trading Tips With plenty of biotech stocks still trading for peanuts and coffers overflowing at the major pharma's, more M&A activity is guaranteed. And while betting on a buyout may be a fool's errand, there are plenty of biotech stocks out there are on my best stocks to invest in list anyway. A buyout would be icing on the cake. * Morgan Stanley: 7 Risky Stocks to Sell Now But which ones have the potential to snagged up because they are so good? Here are five biotech stocks that could be buy-out candidates. Source: Shutterstock ### Seattle Genetics (SGEN) With oncology and cancer on the minds of many of the biggest names pharma, biotech stock Seattle Genetics (NASDAQ:SGEN) could once again be in play. SGEN has one drug available for patients -- Adcetris -- which is used to treat Stage III/IV classical Hodgkin lymphoma. Sales of Adcetris continue to grow rapidly. In the last reported quarter, revenues for the drug jumped by over 60% year-over-year. Even better is that number of indications, combinations and other uses for Adcetris have grown like weeds. SGEN continue to rack up more approvals and "breakthrough" designations for the drug. All of this has only made the medicine more lucrative for the biotech stock. As if that wasn't enough for big pharma to be salivating at the firm, Seattle Genetics has been able to pivot its technology towards other forms of cancer. The firm has numerous drugs targeting urothelial, cervical, breast and multiple myeloma cancer varieties. Here again, SGEN has been quite successful in moving its drugs through the FDA's hoops. Given growing sales of Adcetris and its heavy-duty cancer-focused pipeline, any biopharma looking to make a splash in oncology would seriously be considering SGEN stock. With a market cap of just over $11 billion, Seattle Genetics could one of the next biotech stocks to be bought out. Source: Shutterstock ### Agios Pharmaceuticals (AGIO) Keeping with the cancer buy-out theme, Agios Pharmaceuticals (NASDAQ:AGIO) makes an intriguing biotech buyout candidate. AGIO has two cancer therapies on the market. Its latest, Tibsovo, has been approved for those acute myeloid leukemia patients with an IDH1 mutation. The other -- Idhifa -- is for acute myeloid leukemia patients who also test positive for an IDH2 mutation. The firm basically has a one-two punch for this specific variety of leukemia. And while the drugs are new, prescriptions are growing, with Tibsovo seeing a 100% quarter-over-quarter increase in its short life span. That makes it a buyout candidate alone. Tibsovo is wholly owned by Agios. However, the real kicker is that Idhifa came via a partnership with Celgene. Celgene -- soon to be Bristol Meyers -- must continue to pay royalties on sales from the drug via a tiered structure that gets into the mid-teens. Given its buyout of CELG, BMY may just want to control the whole pie, and with AGIO's market cap sitting at just over $3 billion, it's an easy pill to swallow. And with the two medicines, BMY would be getting a healthy pipeline of additional cancer therapies as well as some rare disease work for a song. * 10 Stocks You Can Set and Forget (Even In This Market) Given that, there's a good chance that AGIO gets the nod. No wonder why shares have jumped higher since both CELG's and LOXO's buyout bids. Source: Shutterstock ### Jazz Pharmaceuticals (JAZZ) It's very rare to find biotech stocks trading for bargain-basement valuations. But that's just what is happening at Jazz Pharmaceuticals (NASDAQ:JAZZ). Today, you can snag JAZZ stock for forward P/E of under 10. JAZZ has five drugs on the market, with narcolepsy drug Xyrem being a blockbuster. Sales of Xyrem continue to grow and are expected to surpass $1.4 billion this year. At the same time, its portfolio of hematology/oncology drugs are proven to be winners as well and are helping JAZZ realize a double-digit EPS growth rate. Acute myeloid leukemia treatment Vyxeos, which only launched last year, is set to pull in roughly $100 million in sales for the full year 2018 and more than $200 million this year. Adding to this is JAZZ's pending March approval for its new drug covering excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Another late-stage candidate for cataplexy in narcolepsy should hit regulatory approval at the end of the year. With a rich drug portfolio and pipeline, JAZZ is a rarity among biotech stocks. It's profitable -- so much so that the firm has authorized a $400 million buyback program. That's after it already repurchased over $600 million in shares. Analysts estimate that a dividend could even be coming next. Featuring a market cap of less than $8 billion, JAZZ would be an easy and profitable tuck-in for almost any big pharma stock. Source: Shutterstock ### Neurocrine Biosciences (NBIX) A rare miss for Neurocrine Biosciences (NASDAQ:NBIX) sent shares crashing this year and left the firm with a $7.5 billion market cap. But NBIX's pain could end up being AbbVie's (NASDAQ:ABBV) gain. Over the summer, NBIX and ABBV received an FDA approval for their drug Orilissa, which is used in the treatment of pain associated with endometriosis. The drug is currently wrapping up trials for the treatment of uterine fibroids. Analysts think the drug has blockbuster potential with annual sales of around $1 billion. On its own, NBIX has a blockbuster in Ingrezza. The drug is used to treat tardive dyskinesia -- which is marked by jerky movements of the face and body out of a patient's control. The problem is tardive dyskinesia is a side effect of many depression, schizophrenia and other mental health drugs. This is a huge market, and Ingrezza sales are taking off. Management at Neurocrine estimates that they'll be able to pull in over $400 million in Ingrezza sales in 2018. And NBIX has a full pipeline of other drugs in various stages of trials. With a buyout, ABBV gets full access to Orilissa without royalty and milestone fees for future indications. Secondly, Ingrezza is quickly becoming a major money marker for NBIX. That would fill a nice hole in AbbVie's revenue stream and would help pay for the deal over the long haul. * The 7 Best Stocks in the Entrepreneur Index All in all, given its low market cap, hefty cash balance and marketed drugs, AbbVie may end up swallowing NBIX whole. Source: Shutterstock ### BioMarin Pharmaceutical (BMRN) When politicians and pundits often talk about the high price of drugs and mention therapies costing more than $400,000 per year, odds are, they are talking about rare and orphan diseases. For biotech stocks, targeting these diseases -- which sometimes can affect very small population sizes -- it can mean plenty of long-term revenues down the road. Given the research required to crack these afflictions, the high drug prices are more than justified. BioMarin (NASDAQ:BMRN) is one biotech stock that has made rare diseases its specialty. The firm has seven drugs on the market targeting illnesses such as phenylketonuria and Batten disease. Rare disease medications come with longer exclusivity rights and by focusing here, BMRN basically ensures patient protection versus generic competition. At the same time, these drugs pull in some big-time revenues. For example, this year, BioMarin expects to make more than $1.5 billion in sales with its top five drugs. Meanwhile, the biotech stocks pipeline is rich as well with drugs for hemophilia and sanfilippo in late-stage trials. Because of its focus, profitability and rich rare disease pipeline, BioMarin has long been considered a buy candidate. With big pharma finally starting to spend some dough, that takeover may finally happen. At the time of writing, Aaron Levitt had a long position in CELG and JAZZ ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks You Can Set and Forget (Even In This Market) * 10 Virtual Assistants for the Future of Smart Homes * 7 5G Stocks to Buy as the Race for Spectrum Tightens Compare Brokers The post 5 Biotech Stocks That Could Face M&A Next! appeared first on InvestorPlace.